Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 17/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 11/20 | 0.32 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558824 | 1.00 | NOS2 (0.35) | NOS2TSHRNPC1HSD17B10NOS1 | |
| SCHEMBL3556830 | 1.00 | NOS2 (0.35) | NOS2TSHRNPC1HSD17B10NOS1 | |
| SCHEMBL3568583 | 0.93 | NOS2 (0.35) | NOS2TSHRNPC1HSD17B10NOS1 | |
| SCHEMBL3614975 | 0.81 | NOS2 (0.45) | NOS2NOS1 | |
| SCHEMBL3556345 | 0.76 | NOS2 (0.55) | NOS2NOS1CD38 | |
| SCHEMBL3566903 | 0.75 | NOS2 (0.50) | NOS2NOS1 | |
| SCHEMBL3567894 | 0.74 | NOS2 (0.56) | NOS2NOS1 | |
| SCHEMBL3556825 | 0.73 | NOS2 (0.58) | NOS2NOS1 | |
| SCHEMBL3559911 | 0.73 | NOS2 (0.58) | NOS2NOS1 | |
| SCHEMBL3558821 | 0.73 | NOS2 (0.58) | NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | NOS2 2/4885TSHR 788/4885NPC1 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.